BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21597719)

  • 1. Breast-tumor xenograft targeting and therapy studies using radiolabeled chimeric anti-cea monoclonal-antibody t84.66.
    Esteban J; Raubitschek A; Felder B; Williams L; Wong J; Shively J
    Oncol Rep; 1995 Mar; 2(2):237-42. PubMed ID: 21597719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
    J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.
    Wong JY; Williams LE; Yamauchi DM; Odom-Maryon T; Esteban JM; Neumaier M; Wu AM; Johnson DK; Primus FJ; Shively JE
    Cancer Res; 1995 Dec; 55(23 Suppl):5929s-5934s. PubMed ID: 7493373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
    Yazaki PJ; Sherman MA; Shively JE; Ikle D; Williams LE; Wong JY; Colcher D; Wu AM; Raubitschek AA
    Protein Eng Des Sel; 2004 May; 17(5):481-9. PubMed ID: 15316127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
    Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
    J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha.
    Robert B; Mach JP; Mani JC; Ychou M; Folli S; Artus JC; Pèlegrin A
    Cancer Res; 1996 Oct; 56(20):4758-65. PubMed ID: 8840995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
    Wong JY; Somlo G; Odom-Maryon T; Williams LE; Liu A; Yamauchi D; Wu AM; Yazaki P; Wilczynski S; Shively JE; Forman S; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3224s-3231s. PubMed ID: 10541368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
    Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoembryonic antigen expression of resurgent human colon carcinoma after treatment with therapeutic doses of 90Y-alpha-carcinoembryonic antigen monoclonal antibody.
    Esteban JM; Kuhn JA; Felder B; Wong JY; Battifora H; Beatty JD; Wanek PM; Shively JE
    Cancer Res; 1991 Jul; 51(14):3802-6. PubMed ID: 2065334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-specific-activity 111In-labeled anticarcinoembryonic antigen monoclonal antibody: biodistribution and imaging in nude mice bearing human colon cancer xenografts.
    Jakowatz JG; Beatty BG; Vlahos WG; Porudominsky D; Philben VJ; Williams LE; Paxton RJ; Shively JE; Beatty JD
    Cancer Res; 1985 Nov; 45(11 Pt 2):5700-6. PubMed ID: 4053043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice.
    Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD
    Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
    Sundaresan G; Yazaki PJ; Shively JE; Finn RD; Larson SM; Raubitschek AA; Williams LE; Chatziioannou AF; Gambhir SS; Wu AM
    J Nucl Med; 2003 Dec; 44(12):1962-9. PubMed ID: 14660722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
    Abuqayyas L; Balthasar JP
    AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma.
    Buchegger F; Mach JP; Pèlegrin A; Gillet M; Vogel CA; Buclin T; Ryser JE; Delaloye B; Delaloye AB
    J Nucl Med; 1995 Mar; 36(3):420-9. PubMed ID: 7884504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting strategies for cancer radiotherapy.
    Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
    Wong JY; Chu DZ; Williams LE; Yamauchi DM; Ikle DN; Kwok CS; Liu A; Wilczynski S; Colcher D; Yazaki PJ; Shively JE; Wu AM; Raubitschek AA
    Clin Cancer Res; 2004 Aug; 10(15):5014-21. PubMed ID: 15297402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.